These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

303 related articles for article (PubMed ID: 30579871)

  • 1. Cyclin-dependent kinase 9 (CDK9) is a novel prognostic marker and therapeutic target in osteosarcoma.
    Ma H; Seebacher NA; Hornicek FJ; Duan Z
    EBioMedicine; 2019 Jan; 39():182-193. PubMed ID: 30579871
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cyclin-dependent kinase 9 (CDK9) is a novel prognostic marker and therapeutic target in ovarian cancer.
    Wang J; Dean DC; Hornicek FJ; Shi H; Duan Z
    FASEB J; 2019 May; 33(5):5990-6000. PubMed ID: 30726104
    [TBL] [Abstract][Full Text] [Related]  

  • 3. CDK9 is a prognostic marker and therapeutic target in pancreatic cancer.
    Kretz AL; Schaum M; Richter J; Kitzig EF; Engler CC; Leithäuser F; Henne-Bruns D; Knippschild U; Lemke J
    Tumour Biol; 2017 Feb; 39(2):1010428317694304. PubMed ID: 28231737
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cyclin E1 is a prognostic biomarker and potential therapeutic target in osteosarcoma.
    Wei R; Thanindratarn P; Dean DC; Hornicek FJ; Guo W; Duan Z
    J Orthop Res; 2020 Sep; 38(9):1952-1964. PubMed ID: 32162720
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prognostic value of tumor suppressors in osteosarcoma before and after neoadjuvant chemotherapy.
    Robl B; Pauli C; Botter SM; Bode-Lesniewska B; Fuchs B
    BMC Cancer; 2015 May; 15():379. PubMed ID: 25956431
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Targeting CDK9: A novel biomarker in the treatment of endometrial cancer.
    He S; Fang X; Xia X; Hou T; Zhang T
    Oncol Rep; 2020 Nov; 44(5):1929-1938. PubMed ID: 32901849
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Overexpression of EZH2 is associated with the poor prognosis in osteosarcoma and function analysis indicates a therapeutic potential.
    Sun R; Shen J; Gao Y; Zhou Y; Yu Z; Hornicek F; Kan Q; Duan Z
    Oncotarget; 2016 Jun; 7(25):38333-38346. PubMed ID: 27223261
    [TBL] [Abstract][Full Text] [Related]  

  • 8. CUL4A expression in pediatric osteosarcoma tissues and its effect on cell growth in osteosarcoma cells.
    Li X; Xu R; Liu H; Fang K
    Tumour Biol; 2016 Jun; 37(6):8139-44. PubMed ID: 26715273
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Targeting cyclin-dependent kinase 9 sensitizes medulloblastoma cells to chemotherapy.
    Song H; Bhakat R; Kling MJ; Coulter DW; Chaturvedi NK; Ray S; Joshi SS
    Biochem Biophys Res Commun; 2019 Dec; 520(2):250-256. PubMed ID: 31594641
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Is CDK9 a promising target for both primary and metastatic osteosarcoma?
    Qin JJ
    EBioMedicine; 2019 Feb; 40():27-28. PubMed ID: 30651218
    [No Abstract]   [Full Text] [Related]  

  • 11. LncRNA SOX2-OT is a novel prognostic biomarker for osteosarcoma patients and regulates osteosarcoma cells proliferation and motility through modulating SOX2.
    Wang Z; Tan M; Chen G; Li Z; Lu X
    IUBMB Life; 2017 Nov; 69(11):867-876. PubMed ID: 28960757
    [TBL] [Abstract][Full Text] [Related]  

  • 12. pFAK-Y397 overexpression as both a prognostic and a predictive biomarker for patients with metastatic osteosarcoma.
    Thanapprapasr K; Nartthanarung A; Thanapprapasr D; Jinawath A
    PLoS One; 2017; 12(8):e0182989. PubMed ID: 28846700
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Platelet-derived growth factor receptor as a prognostic marker and a therapeutic target for imatinib mesylate therapy in osteosarcoma.
    Kubo T; Piperdi S; Rosenblum J; Antonescu CR; Chen W; Kim HS; Huvos AG; Sowers R; Meyers PA; Healey JH; Gorlick R
    Cancer; 2008 May; 112(10):2119-29. PubMed ID: 18338812
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Targeting regulation of cyclin dependent kinase 9 as a novel therapeutic strategy in synovial sarcoma.
    Li X; Seebacher NA; Xiao T; Hornicek FJ; Duan Z
    J Orthop Res; 2019 Feb; 37(2):510-521. PubMed ID: 30488489
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical value of signal transducers and activators of transcription 3 (STAT3) gene expression in human osteosarcoma.
    Wang YC; Zheng LH; Ma BA; Zhou Y; Zhang MH; Zhang DZ; Fan QY
    Acta Histochem; 2011 Jul; 113(4):402-8. PubMed ID: 20546860
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Characterization of molecular and cellular functions of the cyclin-dependent kinase CDK9 using a novel specific inhibitor.
    Albert TK; Rigault C; Eickhoff J; Baumgart K; Antrecht C; Klebl B; Mittler G; Meisterernst M
    Br J Pharmacol; 2014 Jan; 171(1):55-68. PubMed ID: 24102143
    [TBL] [Abstract][Full Text] [Related]  

  • 17. MicroRNA‑106a regulates the proliferation and invasion of human osteosarcoma cells by targeting VNN2.
    Chen Y; Huang T; Yang X; Liu C; Li P; Wang Z; Zhi S
    Oncol Rep; 2018 Oct; 40(4):2251-2259. PubMed ID: 30066949
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Activation of signal transducer and activator of transcription 3 (Stat3) pathway in osteosarcoma cells and overexpression of phosphorylated-Stat3 correlates with poor prognosis.
    Ryu K; Choy E; Yang C; Susa M; Hornicek FJ; Mankin H; Duan Z
    J Orthop Res; 2010 Jul; 28(7):971-8. PubMed ID: 20063378
    [TBL] [Abstract][Full Text] [Related]  

  • 19. High Expression of XRCC6 Promotes Human Osteosarcoma Cell Proliferation through the β-Catenin/Wnt Signaling Pathway and Is Associated with Poor Prognosis.
    Zhu B; Cheng D; Li S; Zhou S; Yang Q
    Int J Mol Sci; 2016 Jul; 17(7):. PubMed ID: 27455247
    [TBL] [Abstract][Full Text] [Related]  

  • 20. p27 Is a Candidate Prognostic Biomarker and Metastatic Promoter in Osteosarcoma.
    Li Y; Nakka M; Kelly AJ; Lau CC; Krailo M; Barkauskas DA; Hicks JM; Man TK
    Cancer Res; 2016 Jul; 76(13):4002-11. PubMed ID: 27197201
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.